Tocilizumab gives new hope for arthritis patients

 

Clinical trial results described as "striking and exciting" could lead to new treatment options for rheumatoid arthritis.

The antibody drug tocilizumab was almost four times more likely to halt progression of the condition than the most widely prescribed alternative.

It also achieved significantly greater reduction in disease signs and symptoms after six months.

Scientists compared tocilizumab, marketed as RoActemra, with the "anti-TNF" drug adalimumab (Humira).

The drugs were tested in a group of 326 patients unable to take the mainstay treatment for rheumatoid arthritis (RA), methotrexate (MTX)

MTX is ruled out for roughly a third of patients, many of whom suffer unbearable side effects such as vomiting, hair loss and mouth ulcers.

Currently, such individuals generally move onto anti-TNF drugs, which target a molecule called tumour necrosis factor that promotes inflammation.

Tocilizumab works in a completely different way by targeting another inflammatory protein, interleukin six (IL-6).

Consultant rheumatologist Professor Paul Emery, from the University of Leeds, who took part in the Adacta trial, said: "These results are impressive and important for the 30% of patients with RA who cannot take methotrexate.

"In RA, disease remission is the goal of therapy.

"However, for varied reasons, many patients fail to achieve this goal.

"Adacta, which compared two active biologics as monotherapies (in methotrexate intolerant patients), has produced striking results and the results help in choosing the right drug for the right patient."

The findings were presented in Berlin at Eular, the annual meeting of the European Congress of Rheumatology.

Professor John Isaacs, a rheumatology expert from the University of Newcastle, said: "These results are very important and exciting.

"For the tens of thousands of patients in the UK that can't take methotrexate, RoActemra will offer them an increased chance of remission, which is the ultimate goal of rheumatoid arthritis treatment.

"This study is the first time a treatment has gone 'head to head' with an anti-TNF in this setting, and to show a significant increase in patients achieving remission is very impressive."

At £9,500 per patient per year, RoActemra costs about the same as Humira.

The NHS cost-effectiveness watchdog Nice (National Institute for health and Clinical Excellence) has already approved of RoActemra when combined with methotrexate.

The new results may lead to the drug being given to larger numbers of patients on its own.

An estimated 646,000 people in the UK have RA, a painful and disabling condition caused by the immune system attacking the joints.

Of those newly diagnosed, around a half will be unable to work within 10 years.

Ailsa Bosworth, chief executive of the National Rheumatoid Arthritis Society, said: "With any medical condition, remission is the number one target. Curing the person of their illness and enabling them to get on with their life is the ultimate goal.

"For those with rheumatoid arthritis however, there is no cure, they will always have rheumatoid arthritis. Remission for those with RA does not mean the disease has gone, it just means it is better controlled.

"The key to the most successful outcome is an early diagnosis and early treatment with the most effective drug(s)."

PA

Voices
voices
News
general electionThis quiz matches undecided voters with the best party for them
Arts and Entertainment
Keira Knightley and Matthew Macfadyen starred in the big screen adaptation of Austen's novel in 2005
tvStar says studios are forcing actors to get buff for period roles
News
Prince William and his wife Catherine, Duchess of Cambridge show their newly-born daughter, their second child, to the media outside the Lindo Wing at St Mary's Hospital in central London, on 2 May 2015.
news
Life and Style
ebookNow available in paperback
ebooks
ebookPart of The Independent’s new eBook series The Great Composers
  • Get to the point
Latest stories from i100
Have you tried new the Independent Digital Edition apps?

ES Rentals

    Independent Dating
    and  

    By clicking 'Search' you
    are agreeing to our
    Terms of Use.

    iJobs Job Widget
    iJobs General

    Ashdown Group: Trainee Consultant - Surrey/ South West London

    £22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

    Ashdown Group: Trainee Consultant - Surrey / South West London

    £22000 per annum + pension,bonus,career progression: Ashdown Group: An establi...

    Ashdown Group: Recruitment Consultant / Account Manager - Surrey / SW London

    £40000 per annum + realistic targets: Ashdown Group: A thriving recruitment co...

    Ashdown Group: Part-time Payroll Officer - Yorkshire - Professional Services

    £25000 per annum: Ashdown Group: A successful professional services firm is lo...

    Day In a Page

    Fishing for votes with Nigel Farage: The Ukip leader shows how he can work an audience as he casts his line to the disaffected of Grimsby

    Fishing is on Nigel Farage's mind

    Ukip leader casts a line to the disaffected
    Who is bombing whom in the Middle East? It's amazing they don't all hit each other

    Who is bombing whom in the Middle East?

    Robert Fisk untangles the countries and factions
    China's influence on fashion: At the top of the game both creatively and commercially

    China's influence on fashion

    At the top of the game both creatively and commercially
    Lord O’Donnell: Former cabinet secretary on the election and life away from the levers of power

    The man known as GOD has a reputation for getting the job done

    Lord O'Donnell's three principles of rule
    Rainbow shades: It's all bright on the night

    Rainbow shades

    It's all bright on the night
    'It was first time I had ever tasted chocolate. I kept a piece, and when Amsterdam was liberated, I gave it to the first Allied soldier I saw'

    Bread from heaven

    Dutch survivors thank RAF for World War II drop that saved millions
    Britain will be 'run for the wealthy and powerful' if Tories retain power - Labour

    How 'the Axe' helped Labour

    UK will be 'run for the wealthy and powerful' if Tories retain power
    Rare and exclusive video shows the horrific price paid by activists for challenging the rule of jihadist extremists in Syria

    The price to be paid for challenging the rule of extremists

    A revolution now 'consuming its own children'
    Welcome to the world of Megagames

    Welcome to the world of Megagames

    300 players take part in Watch the Skies! board game in London
    'Nymphomaniac' actress reveals what it was really like to star in one of the most explicit films ever

    Charlotte Gainsbourg on 'Nymphomaniac'

    Starring in one of the most explicit films ever
    Robert Fisk in Abu Dhabi: The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers

    Robert Fisk in Abu Dhabi

    The Emirates' out-of-sight migrant workers helping to build the dream projects of its rulers
    Vince Cable interview: Charging fees for employment tribunals was 'a very bad move'

    Vince Cable exclusive interview

    Charging fees for employment tribunals was 'a very bad move'
    Iwan Rheon interview: Game of Thrones star returns to his Welsh roots to record debut album

    Iwan Rheon is returning to his Welsh roots

    Rheon is best known for his role as the Bastard of Bolton. It's gruelling playing a sadistic torturer, he tells Craig McLean, but it hasn't stopped him recording an album of Welsh psychedelia
    Morne Hardenberg interview: Cameraman for BBC's upcoming show Shark on filming the ocean's most dangerous predator

    It's time for my close-up

    Meet the man who films great whites for a living
    Increasing numbers of homeless people in America keep their mobile phones on the streets

    Homeless people keep mobile phones

    A homeless person with a smartphone is a common sight in the US. And that's creating a network where the 'hobo' community can share information - and fight stigma - like never before